Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) – Analysts at Roth Capital lifted their FY2016 earnings per share estimates for Pieris Pharmaceuticals in a research note issued on Thursday. Roth Capital analyst J. Pantginis now expects that the firm will post earnings per share of ($0.52) for the year, up from their prior estimate of ($0.54). Roth Capital has a “Buy” rating and a $6.00 price target on the stock. Roth Capital also issued estimates for Pieris Pharmaceuticals’ Q4 2016 earnings at ($0.15) EPS, FY2017 earnings at ($0.58) EPS, FY2018 earnings at ($0.63) EPS, FY2019 earnings at ($0.76) EPS and FY2020 earnings at ($0.67) EPS.

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Separately, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $10.00 target price on shares of Pieris Pharmaceuticals in a research report on Wednesday, September 28th.

Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.57 on Monday. The company has a 50-day moving average of $1.62 and a 200 day moving average of $1.68. Pieris Pharmaceuticals has a one year low of $1.26 and a one year high of $3.08. The firm’s market cap is $67.60 million.

Several institutional investors have recently made changes to their positions in the stock. BVF Inc. IL boosted its position in shares of Pieris Pharmaceuticals by 321.2% in the third quarter. BVF Inc. IL now owns 1,016,593 shares of the company’s stock valued at $1,858,000 after buying an additional 775,241 shares during the last quarter. Morgan Stanley boosted its position in shares of Pieris Pharmaceuticals by 74,230.0% in the third quarter. Morgan Stanley now owns 74,330 shares of the company’s stock valued at $136,000 after buying an additional 74,230 shares during the last quarter. Lombard Odier Asset Management USA Corp boosted its position in shares of Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock valued at $5,099,000 after buying an additional 533,965 shares during the last quarter. Sabby Management LLC boosted its position in shares of Pieris Pharmaceuticals by 823.4% in the second quarter. Sabby Management LLC now owns 1,615,992 shares of the company’s stock valued at $2,602,000 after buying an additional 1,440,992 shares during the last quarter. Finally, Frontier Wealth Management LLC bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $137,000. Institutional investors and hedge funds own 44.91% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

5 Day Chart for NASDAQ:PIRS

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.